A gene-editing technology that is being explored by scientists worldwide as a way of removing and replacing gene defects might inadvertently increase cancer risk in cells, scientists warned.

U.S. appeals court judges appear divided over whether to allow a research center affiliated with MIT and Harvard to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.

Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.

CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.

Backed by financing from a collaboration with Novartis and an $83 million financing round, Homology Medicines is moving to a new facility with more than triple the space of its headquarters.

Barely a week after announcing it was moving into a new corporate headquarters, Sangamo Therapeutics announced that the company has dosed the first patient in its Phase I/II gene therapy trial.

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Astellas Institute for Regenerative Medicine and Universal Cells Inc. have entered into an exclusive worldwide license agreement to research, develop and commercialize a novel cell therapy for an undisclosed indication. The collaboration will utilize Universal Cells’ Universal Donor Cell technology to create cell therapy products that can be administered to any recipient without the need for Human Leukocyte Antigen matching.

Are there unintended consequences of gene editing? A paper published in Nature Methods indicates there are and that news sent share prices of CRISPR, Editas Medicine and Intellia tumbling.